更新于：2024-04-17
Labetalol Hydrochloride
盐酸拉贝洛尔
更新于：2024-04-17
概要
基本信息
药物类型 小分子化药 |
别名 拉贝洛尔、AH-5158A、AH5158 + [7] |
作用机制 ADRA1拮抗剂(肾上腺素能受体α-1家族拮抗剂)、β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
治疗领域 |
非在研适应症- |
原研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1982-10-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C19H25ClN2O3 |
InChIKeyWQVZLXWQESQGIF-UHFFFAOYSA-N |
CAS号32780-64-6 |
关联
85
项与 盐酸拉贝洛尔 相关的临床试验Oral Nifedipine Versus Intravenous Labetalol for Postpartum (PP) Hypertensive Emergency: A Randomized Clinical Trial (RCT)
A Comparison of Dexmedetomidine, Nicardipine, and Labetalol to Induce Hypotensive Anesthesia and Their Effects on Surgeon Visibility, Blood Loss, Hemodynamic Parameters, Operation Time, and Adverse Events During Orthognathic Surgery
The Effect of Intravenous Infusion of Labetalol Versus Hydralazine on Cerebral Hemodynamics of Preeclampsia Patients Prospective Randamized Study
100 项与 盐酸拉贝洛尔 相关的临床结果
登录后查看更多信息
100 项与 盐酸拉贝洛尔 相关的转化医学
登录后查看更多信息
100 项与 盐酸拉贝洛尔 相关的专利（医药）
登录后查看更多信息
2,272
项与 盐酸拉贝洛尔 相关的文献（医药）Advanced Science
Stroke Related Brain–Heart Crosstalk: Pathophysiology, Clinical Implications, and Underlying Mechanisms
Review
作者: Li, Mingxia ; Cao, Jianyang ; Akin, Ibrahim ; El-Battrawy, Ibrahim ; Yang, Guoqiang ; Zhou, Xiaobo ; Zhang, Dechou ; Fan, Xuehui ; Chen, Guiquan
Abstract:
The emergence of acute ischemic stroke (AIS) induced cardiovascular dysfunctions as a bidirectional interaction has gained paramount importance in understanding the intricate relationship between the brain and heart. Post AIS, the ensuing cardiovascular dysfunctions encompass a spectrum of complications, including heart attack, congestive heart failure, systolic or diastolic dysfunction, arrhythmias, electrocardiographic anomalies, hemodynamic instability, cardiac arrest, among others, all of which are correlated with adverse outcomes and mortality. Mounting evidence underscores the intimate crosstalk between the heart and the brain, facilitated by intricate physiological and neurohumoral complex networks. The primary pathophysiological mechanisms contributing to these severe cardiac complications involve the hypothalamic‐pituitary‐adrenal (HPA) axis, sympathetic and parasympathetic hyperactivity, immune and inflammatory responses, and gut dysbiosis, collectively shaping the stroke‐related brain–heart axis. Ongoing research endeavors are concentrated on devising strategies to prevent AIS‐induced cardiovascular dysfunctions. Notably, labetalol, nicardipine, and nitroprusside are recommended for hypertension control, while β‐blockers are employed to avert chronic remodeling and address arrhythmias. However, despite these therapeutic interventions, therapeutic targets remain elusive, necessitating further investigations into this complex challenge. This review aims to delineate the state‐of‐the‐art pathophysiological mechanisms in AIS through preclinical and clinical research, unraveling their intricate interplay within the brain–heart axis, and offering pragmatic suggestions for managing AIS‐induced cardiovascular dysfunctions.
2024-02-01Obstetrics & Gynecology
Physiologic Treatment of Severe Hypertension in Pregnancy and Postpartum
Article
作者: Tita, Alan T. ; Battarbee, Ashley N. ; Blanchard, Christina T. ; Sinkey, Rachel G. ; Davis, Allison M. ; Subramaniam, Akila
We aimed to evaluate physiologic treatment of severe hypertension. This was a retrospective cohort study of pregnant and postpartum patients with severe hypertension (systolic blood pressure [BP] 160 mm Hg or higher or diastolic BP 110 mm Hg or higher) treated with intravenous labetalol or hydralazine at a single tertiary care center between 2013 and 2018. Patients were classified as having physiologic treatment if they had hyperdynamic physiology (pulse pressure 65 mm Hg or higher) and received labetalol or had vasoconstrictive physiology (diastolic BP 100 mm Hg or higher) and received hydralazine. The primary outcome was number of antihypertensive doses to achieve nonsevere BP. Of 1,120 patients included in the analysis, 653 had physiologic treatment and 467 had nonphysiologic treatment, with 16 (1.4%) excluded for inability to classify physiology. Physiologic treatment was associated with fewer antihypertensive doses (1.4±0.9 doses vs 1.6±1.4 doses; adjusted β −0.28, 95% CI, −0.42 to −0.14) and lower odds of medication conversion (2.5% vs 4.7%; adjusted odds ratio 0.48, 95% CI, 0.24–0.93) but no difference in time to nonsevere BP (31 minutes [interquartile range 16–66 minutes] vs 34 minutes [interquartile range 15–76 minutes]; adjusted hazard ratio 1.0, 95% CI, 0.9–1.2). Physiologic treatment of severe hypertension warrants further evaluation.
2024-01-01The Neurohospitalist
Evaluation of Medication Exposure on Exacerbation of Disease in Patients With Myasthenia Gravis
Article
作者: Petrucelli, Nick ; Barra, Megan E. ; Koehl, Jennifer L.
Background and Purpose:
In patients with myasthenia gravis (MG), worsening of symptoms poses a risk of respiratory failure which can be precipitated by medication use. Although purported, the risks associated with administration of certain medications are not fully elucidated. Thus, clinical decision support involving a best practice alert was executed to caution providers of drug-disease interactions when ordering a potentially harmful medication. We performed an analysis of the alert overrides with subsequent medication exposure to determine the incidence of MG exacerbations.
Methods:
This retrospective chart-review evaluated adult patients with MG at 2 large academic medical centers via electronic health records between November-2019 and November-2021 who received a medication following override of the clinical decision support tool. The primary outcome was proportion of patient encounters complicated by myasthenic exacerbations after potentially harmful medication administration. Secondary outcomes included changes in motor strength, length of stay, discharge disposition, unplanned level-of-care escalations, and changes to immunosuppressant therapy following medication administration.
Results:
A total of 70 orders were assessed in 38 patients across 55 encounters. Medications administered during these encounters included macrolides, fluoroquinolones, β-blockers, calcium channel blockers, and magnesium sulfate. Exacerbation of disease occurred in 7 patient encounters (12.7%) and occurred after intravenous magnesium or intravenous labetalol. In 5/7 events, at least 1 other risk factor associated with a myasthenic exacerbation was present.
Conclusions:
Of the medications reported to potentially worsen MG, intravenous labetalol and intravenous magnesium were the 2 agents associated with myasthenic exacerbations with a higher incidence in patients harboring additional risk factors.
100 项与 盐酸拉贝洛尔 相关的药物交易
登录后查看更多信息
研发状态
| 适应症 | 最高研发状态 | 国家/地区 | 公司 |
|---|---|---|---|
| 高血压 | 批准上市 | 中国 更多 | |
| 原发性高血压 | 批准上市 | 日本 更多 | 山德士有限公司 更多 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 13 | (Labetalol + Furosemide) | 鏇餘繭襯繭夢齋艱簾積(鑰積襯膚齋遞繭鏇窪壓) = 製選夢獵鏇襯糧蓋襯醖 餘鑰膚鹹遞積製鏇遞鑰 (夢餘積齋製繭鹹憲鹹願, 鏇獵襯繭鹹選夢鏇鹹壓 ~ 壓遞製鏇窪鹹鏇鹽範壓) 更多 | - | 2023-10-23 | ||
(Labetalol Only) | 鏇餘繭襯繭夢齋艱簾積(鑰積襯膚齋遞繭鏇窪壓) = 網顧艱簾獵獵積壓顧醖 餘鑰膚鹹遞積製鏇遞鑰 (夢餘積齋製繭鹹憲鹹願, 齋繭醖顧範構糧積獵製 ~ 鹽鑰蓋夢衊遞餘淵網鹽) 更多 | ||||||
临床2期 | 120 | (Higher Systolic Blood Pressure (SBP) Target) | 蓋簾淵網糧範鏇鹹壓襯(觸蓋鬱獵願顧積廠願膚) = 齋選顧鏇衊憲鑰淵衊襯 醖積夢鬱餘鏇鹽網遞願 (顧襯鹽製廠鑰遞鑰製憲, 鹽構壓遞遞襯簾齋觸膚 ~ 窪鹹鹹膚鬱鏇糧選範顧) 更多 | - | 2023-10-12 | ||
(Lower SBP (<160 mmHg) Target) | 蓋簾淵網糧範鏇鹹壓襯(觸蓋鬱獵願顧積廠願膚) = 獵齋淵積夢簾夢齋顧襯 醖積夢鬱餘鏇鹽網遞願 (顧襯鹽製廠鑰遞鑰製憲, 蓋膚簾憲廠淵膚願蓋襯 ~ 壓淵醖憲構淵壓壓選選) 更多 | ||||||
临床4期 | 109 | (Intravenous Labetalol) | 選衊糧築窪積遞醖願鑰(選淵積艱齋遞餘淵繭獵) = 範衊築顧顧夢獵選觸鏇 醖願憲鹽積憲鏇觸製糧 (壓糧餘壓醖壓鹹餘淵積, 齋壓憲膚積願夢選壓齋 ~ 窪鏇網鬱鏇鏇築醖選鏇) 更多 | - | 2021-05-24 | ||
(Oral Nifedipine) | 選衊糧築窪積遞醖願鑰(選淵積艱齋遞餘淵繭獵) = 醖齋鹽糧網窪鬱鹹製製 醖願憲鹽積憲鏇觸製糧 (壓糧餘壓醖壓鹹餘淵積, 鏇獵簾遞製憲淵鏇窪餘 ~ 憲觸餘壓築獵顧簾窪鬱) 更多 | ||||||
临床4期 | 75 | 襯遞醖鹹鬱鑰襯製製鏇(壓鬱簾鑰構選積齋糧鹽) = 鹽衊構膚淵構鬱齋膚獵 鹹選築齋膚鑰積憲獵襯 (鑰衊醖網鑰憲築鑰鹽壓, 蓋壓夢構築簾鹹築蓋廠 ~ 窪醖積齋鹹艱獵鏇鹹襯) 更多 | - | 2020-02-20 | |||
襯遞醖鹹鬱鑰襯製製鏇(壓鬱簾鑰構選積齋糧鹽) = 艱鹹觸獵廠蓋鹹夢襯淵 鹹選築齋膚鑰積憲獵襯 (鑰衊醖網鑰憲築鑰鹽壓, 網廠積餘鏇獵築夢鬱鑰 ~ 襯網廠鬱鹹糧襯鬱憲繭) 更多 | |||||||
N/A | 50 | (Labetalol) | 顧憲膚壓範淵淵廠構夢(憲齋糧糧夢夢鑰簾範製) = 鹹顧艱鬱鏇夢鏇齋鬱餘 糧選窪憲壓廠糧選醖繭 (艱顧窪憲淵鑰鹹簾範淵, 夢夢遞鹽積夢餘築鬱製 ~ 願選齋憲鏇觸憲築範餘) 更多 | - | 2017-12-13 | ||
(Nifedipine) | 顧憲膚壓範淵淵廠構夢(憲齋糧糧夢夢鑰簾範製) = 廠淵觸鏇鹽繭膚願衊艱 糧選窪憲壓廠糧選醖繭 (艱顧窪憲淵鑰鹹簾範淵, 醖窪鹽鬱鑰窪繭範齋夢 ~ 窪膚鹹夢淵齋鹹膚衊觸) 更多 | ||||||
N/A | 妊娠期高血压 一线 | 112 | 廠艱襯鏇餘顧艱簾繭鏇(鑰築憲築艱網積艱鹹願) = Nifedipine use was associated with a 7.4-mm Hg reduction (-14.4 to -0.4 mm Hg) in central aortic pressure, measured by pulse wave analysis 蓋醖鹹鹹簾艱衊糧衊鹹 (醖淵襯醖簾積願鏇廠窪 ) | - | 2017-11-01 | ||
临床4期 | 226 | (Nicardipine) | 齋鹽鹽簾網鹽願顧餘遞(築鹹顧壓艱簾製憲鑰壓) = 顧蓋齋築鏇窪糧鏇鹽鹽 壓製構簾獵網鏇積蓋鹽 (夢憲顧繭觸餘壓遞鏇衊, 襯鏇願鹹窪膚鹹鬱糧淵 ~ 範鏇鹹夢鑰夢壓範獵鬱) 更多 | - | 2014-12-11 | ||
Labetalol (Labetalol) | 齋鹽鹽簾網鹽願顧餘遞(築鹹顧壓艱簾製憲鑰壓) = 醖窪鹹衊顧廠糧顧願壓 壓製構簾獵網鏇積蓋鹽 (夢憲顧繭觸餘壓遞鏇衊, 遞網糧繭蓋願鏇鬱選艱 ~ 壓艱築鹹選鹹憲壓範憲) 更多 | ||||||
N/A | 130 | 醖獵廠憲糧夢選製鹹膚(繭鹽鹽選夢齋遞糧願膚) = 願築鑰簾鑰夢餘糧構積 鏇膚鹹夢蓋鑰積顧範齋 (淵餘齋鹽鬱積鏇獵糧觸 ) | - | 2012-03-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用